| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| P J McGrath, F M Quitkin, D F Klei. Bromocriptine treatment of relapses seen during selective serotonin re-uptake inhibitor treatment of depression. Journal of clinical psychopharmacology. vol 15. issue 4. 1995-12-19. PMID:7593717. |
bromocriptine treatment of relapses seen during selective serotonin re-uptake inhibitor treatment of depression. |
1995-12-19 |
2023-08-12 |
Not clear |
| E A Ottevange. Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study. L'Encephale. vol 21. issue 4. 1995-12-18. PMID:7588171. |
the efficacy of the selective serotonin reuptake inhibitors (ssris) and the tricyclic antidepressants is well established, although data on the efficacy of ssris in severe depression is limited. |
1995-12-18 |
2023-08-12 |
Not clear |
| D J Haleem, A Yasmeen, M A Haleem, A Zafa. 24h withdrawal following repeated administration of caffeine attenuates brain serotonin but not tryptophan in rat brain: implications for caffeine-induced depression. Life sciences. vol 57. issue 19. 1995-12-15. PMID:7475912. |
24h withdrawal following repeated administration of caffeine attenuates brain serotonin but not tryptophan in rat brain: implications for caffeine-induced depression. |
1995-12-15 |
2023-08-12 |
rat |
| D J Haleem, A Yasmeen, M A Haleem, A Zafa. 24h withdrawal following repeated administration of caffeine attenuates brain serotonin but not tryptophan in rat brain: implications for caffeine-induced depression. Life sciences. vol 57. issue 19. 1995-12-15. PMID:7475912. |
in view of a possible role of 5-ht in caffeine-induced depression the effects of repeated administration of high doses of caffeine on brain 5-ht metabolism are investigated in rats. |
1995-12-15 |
2023-08-12 |
rat |
| D J Haleem, A Yasmeen, M A Haleem, A Zafa. 24h withdrawal following repeated administration of caffeine attenuates brain serotonin but not tryptophan in rat brain: implications for caffeine-induced depression. Life sciences. vol 57. issue 19. 1995-12-15. PMID:7475912. |
the findings are discussed as repeated caffeine administration producing adaptive changes in the serotonergic neurons to decrease the conversion of tryptophan to 5-ht and this may precipitate depression particularly in conditions of caffeine withdrawal. |
1995-12-15 |
2023-08-12 |
rat |
| V M Storozhuk, V V Sachenko, J A Kruchenk. Dependence of sensorimotor cortex neuron activity on noradrenergic and serotoninergic transmission in unspecific thalamic nuclei. Neuroscience. vol 68. issue 2. 1995-12-12. PMID:7477943. |
background and evoked impulse activity greatly increased by application of 5-hydroxytryptamine after preliminary lisergamide-induced depression of the impulse activity. |
1995-12-12 |
2023-08-12 |
Not clear |
| M J Villa. [New concepts relating to histochemistry of the serotonergic neural systems of the raphe nucleus]. Acta psiquiatrica y psicologica de America latina. vol 40. issue 4. 1995-12-07. PMID:7484182. |
all these results have expanded our knowledge on the raphe nuclei and suggest that many other substances, apart from serotonin, could be involved in the regulation of processes such as sleep, anxiety and depression. |
1995-12-07 |
2023-08-12 |
Not clear |
| L Staner, M Kerkhofs, D Detroux, S Leyman, P Linkowski, J Mendlewic. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep. vol 18. issue 6. 1995-11-30. PMID:7481419. |
paroxetine (30 mg), a selective serotonin (5-ht) reuptake inhibitor, was compared in a double-blind trial to amitriptyline (150 mg) in a sample of 40 inpatients aged 18-65 years who fulfilled research diagnostic criteria for major depression. |
1995-11-30 |
2023-08-12 |
Not clear |
| M I Wilde, R Whittingto. Paroxetine. A pharmacoeconomic evaluation of its use in depression. PharmacoEconomics. vol 8. issue 1. 1995-11-29. PMID:10155603. |
there has been intense debate about whether the use of paroxetine or other selective serotonin reuptake inhibitors (ssris) as alternatives to tricyclic antidepressants for first-line treatment of depression can be justified, considering their higher acquisition costs. |
1995-11-29 |
2023-08-12 |
Not clear |
| J D Bentkover, J P Feighne. Cost analysis of paroxetine versus imipramine in major depression. PharmacoEconomics. vol 8. issue 3. 1995-11-29. PMID:10155618. |
a simulation decision analytical model was used to compare the annual direct medical costs of treating patients with major depression using the selective serotonin reuptake inhibitor (ssri) paroxetine or the tricyclic antidepressant (tca) imipramine. |
1995-11-29 |
2023-08-12 |
Not clear |
| b' R Krul\\xc3\\xadk, P Bures, Z Fisar, K Fuksov\\xc3\\xa1, J Sikora, D Beitlov\\xc3\\xa. [Ca(2+)-channel blockers and binding of tricyclic antidepressive agents]. Ceskoslovenska psychiatrie. vol 91. issue 3. 1995-11-20. PMID:7553947.' |
mechanism of ca(2+)-channel blockers action in the treatment of depression may be connected rather with changes in signal transduction through serotonin and catecholamine receptor systems than with direct interaction of drugs with binding sites for tricyclic antidepressants. |
1995-11-20 |
2023-08-12 |
human |
| F Fernández-de-Miguel, P Drapea. Synapse formation and function: insights from identified leech neurons in culture. Journal of neurobiology. vol 27. issue 3. 1995-10-17. PMID:7673895. |
the release of 5-ht is quantal, calcium-dependent, and shows activity-dependent facilitation and depression. |
1995-10-17 |
2023-08-12 |
Not clear |
| M B Keller, D L Hank. Anxiety symptom relief in depression treatment outcomes. The Journal of clinical psychiatry. vol 56 Suppl 6. 1995-09-28. PMID:7649969. |
in studies comparing benzodiazepines, monoamine oxidase inhibitors (maois), serotonin selective reuptake inhibitors (ssris), and tricyclic antidepressants (tcas) in the treatment of concurrent anxiety and depression, all have some measure of success depending on the degree of depression and the type of anxiety disorder. |
1995-09-28 |
2023-08-12 |
Not clear |
| J Mendels, F Reimherr, R N Marcus, D L Roberts, R J Francis, S F Anto. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. The Journal of clinical psychiatry. vol 56 Suppl 6. 1995-09-28. PMID:7649971. |
nefazodone hydrochloride, a 5-ht2 receptor antagonist that selectively inhibits serotonin reuptake, was evaluated in a double-blind, dose-finding study of novel design, involving 240 patients with major depression. |
1995-09-28 |
2023-08-12 |
Not clear |
| K Rickels, D S Robinson, E Schweizer, R N Marcus, D L Robert. Nefazodone: aspects of efficacy. The Journal of clinical psychiatry. vol 56 Suppl 6. 1995-09-28. PMID:7649973. |
nefazodone hydrochloride, a 5-ht2 receptor antagonist and serotonin (5-ht) uptake inhibitor, was evaluated in four phase 3 double-blind, imipramine- and placebo-controlled studies involving outpatients with major depression. |
1995-09-28 |
2023-08-12 |
Not clear |
| H H Berendse. Interactions between 5-hydroxytryptamine receptor subtypes: is a disturbed receptor balance contributing to the symptomatology of depression in humans? Pharmacology & therapeutics. vol 66. issue 1. 1995-09-07. PMID:7630928. |
interactions between 5-hydroxytryptamine receptor subtypes: is a disturbed receptor balance contributing to the symptomatology of depression in humans? |
1995-09-07 |
2023-08-12 |
Not clear |
| I Hindmarc. The behavioural toxicity of the selective serotonin reuptake inhibitors. International clinical psychopharmacology. vol 9 Suppl 4. 1995-08-31. PMID:7622818. |
the serotonin reuptake inhibitors (ssris) are generally better tolerated than the traditional tricyclic antidepressants (tcas) in the treatment of major depression. |
1995-08-31 |
2023-08-12 |
Not clear |
| D Baldwin, S Rudg. The role of serotonin in depression and anxiety. International clinical psychopharmacology. vol 9 Suppl 4. 1995-08-31. PMID:7622823. |
the role of serotonin in depression and anxiety. |
1995-08-31 |
2023-08-12 |
Not clear |
| D Baldwin, S Rudg. The role of serotonin in depression and anxiety. International clinical psychopharmacology. vol 9 Suppl 4. 1995-08-31. PMID:7622823. |
recent research has identified that various abnormalities in serotonergic function are involved in the pathogenesis of depression and anxiety, and has facilitated the development of new pharmacological agents with great therapeutic potential, for example the selective serotonin reuptake inhibitors (ssris). |
1995-08-31 |
2023-08-12 |
Not clear |
| P Robert, S A Montgomer. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. International clinical psychopharmacology. vol 10 Suppl 1. 1995-08-30. PMID:7622809. |
the aim of the present study was to determine whether, in patients with depression who had responded favourably to the selective serotonin reuptake inhibitor citalopram, there was a therapeutic benefit in continuation treatment. |
1995-08-30 |
2023-08-12 |
Not clear |